Healthcare Triangle, Inc. (HCTI) - 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2025. Healthcare Triangle, Inc. is a healthcare information technology company providing cloud services, data science, and managed services to the Healthcare and Life Sciences (HCLS) industry. The company operates as a non-accelerated filer and an emerging growth company. During the period, the company completed a significant acquisition of Niyama Healthcare, Inc. (including Ezovion Solutions) and executed a 1-for-249 reverse stock split.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Revenue | $3.49M | $2.41M | $10.75M | $9.51M |
| Gross Profit | $0.62M | $0.72M | $1.44M | $2.63M |
| Gross Margin | 18% | 30% | 13% | 28% |
| Net Loss | $(1.91M) | $(1.25M) | $(4.97M) | $(4.62M) |
| Cash & Equivalents | $1.63M | $0.03M | $1.63M | $0.03M |
| Short-Term Debt | $1.53M | $2.65M | $1.53M | $2.65M |
| Current Ratio | 1.13 | 0.22 | 1.13 | 0.22 |
Note: All figures in thousands of USD unless otherwise noted.
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 45% year-over-year (YoY) to $3.49M, driven primarily by a 155% surge in Software Services revenue ($1.98M vs $0.78M). Managed Services revenue declined 12% YoY.
- Margin Compression: Gross margins contracted significantly from 30% in Q3 2024 to 18% in Q3 2025. Management attributes this to the onboarding of acquired SecureKloud contracts negotiated at lower margins. Margins are expected to improve as new contracts are negotiated at higher rates.
- Expense Increases: Operating expenses rose sharply. Sales and Marketing expenses increased 248% YoY, and General and Administrative (G&A) expenses increased 94% YoY, reflecting investments in scaling the business and integration costs.
- Acquisition Activity: The company acquired Niyama Healthcare, Inc. for a total consideration of $5.7M (cash, stock, and earn-out), adding $5.89M in goodwill and intangibles to the balance sheet.
- Liquidity Improvement: Cash and cash equivalents increased from $20k at year-end 2024 to $1.63M at Q3 2025, supported by $12.6M in net financing proceeds (primarily from a private placement).
Guidance, Outlook, and Risks
- Outlook: Management expects future profit margins to increase materially over the next few quarters as new contracts are negotiated at higher margins. The company is shifting focus toward recurring subscription-based revenues (SaaS) to improve stability.
- Capital Resources: The company believes existing cash and cash equivalents are sufficient to meet working capital needs for the next 12 months.
- Risks:
- Customer Concentration: The top 5 customers accounted for 56% of Q3 2025 revenue.
- Related Party Dependence: Significant balances are due from affiliates (SecureKloud Technologies), totaling $3.5M as of September 30, 2025.
- Debt Obligations: The company has a $1.53M short-term borrowing facility against accounts receivable and contingent consideration liabilities of $1.2M.
- Forward-Looking Uncertainty: Risks include the ability to scale solutions, maintain customer retention, and manage the integration of acquired assets.
Investor Verification Checklist
- Margin Recovery: Verify if gross margins improve in Q4 2025 as management predicts new contracts will offset the low-margin acquired contracts.
- Related Party Receivables: Confirm the collectability and settlement timeline of the $3.5M due from affiliates (SecureKloud Technologies).
- Acquisition Integration: Assess the financial performance of the newly acquired Niyama Healthcare/Ezovion assets and the realization of the $1.2M earn-out.
- Capital Structure: Monitor the exercise of Series A and B warrants and the impact of the recent 1-for-249 reverse stock split on share liquidity.
- Customer Concentration: Evaluate the risk associated with the top 5 customers representing over half of total revenue.